FEDERAL STATE BUDGETARY INSTITUTION "N.N. BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY" OF THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION;SEDA, OVIKOVNA;СЕДА ОВИКОВНА;ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕ
发明人:
Seda, Ovikovna,Седа Овиковна,Maria, Nikolaevna,Мария Николаевна
申请号：
EA201800625
公开号：
EA035633B1
申请日:
2018.12.20
申请国别(地区):
EA
年份:
2020
代理人:
摘要：
The invention relates to medicine, in particular, to oncology, operative gynecology and concerns a method of surgical treatment of patients with advanced ovarian cancer. The objective of the invention is to provide a new method of surgical treatment of patients with advanced ovarian cancer. The method of surgical treatment of patients with advanced ovarian cancer is that a conglomerate consisting of tumors of ovaries, uterus, uterine ligaments, peritoneum of pelvis and parametric cellulose is mobilized by retroperitoneal approach and removed in a single unit with an upper third of vagina. Cardinal and sacrouterine ligaments are transected at the pelvic walls without affecting the lower hypogastric plexus (plexus hypogastricus inferior). Biliary-uterine ligaments are transected near the bladder wall. Uterine artery and vein are transected at the level of their retraction from the internal iliac artery and vein. Pelvic and paraaortic lymph nodes are completely removed as a single unit - total paraaortal and iliac lymph node dissection. 36 patients with stage IIC-IV ovarian cancer were treated in accordance with the claimed method. Within this number: 5 (13.8%) patients had stage II, 30 (83%) patients had stage III, and 1 (2.7%) patient had stage IV disease. In 18 patients, surgical treatment was performed after neoadjuvant chemotherapy, 18 patients were treated immediately after the diagnosis was determined. After surgery, all patients received chemotherapy (CP). The average age of patients was 54.6 years (from 24 to 82 years old). Complete cytoreduction was achieved in 27 (75.7%) patients, optimal cytoreduction (residual tumor sizes from 0.1 to 0.5 cm in diameter) in 9 patients (24.3%). Thus, all patients were operated in the optimal scope. A disease recurrence was detected on average after 24.8 months (from 9 to 42 months) through MRI and US scanning and by the level of CA-125 in the blood. The method according the invention allows achieving the 5-year overall survi
